Immuno-oncology (IO) has been an active area of oncology research. Following US FDA
approval of the first immune checkpoint inhibitor (ICI), ipilimumab (human IgG1 k anti-CTLA …

Oncolytic virus (OV) therapy is an emerging anti-cancer approach that utilizes viruses to
preferentially infect and kill cancer cells, while not harming healthy cells. Vesicular stomatitis …

Oncolytic viruses (OVs) are viral strains that can infect and kill malignant cells while spare
their normal counterparts. OVs can access cells through binding to receptors on their surface …

Vesicular stomatitis virus (VSV) is a prototypic nonsegmented negative-strand RNA virus.
VSV's broad cell tropism makes it a popular model virus for many basic research …

Modern oncotherapy approaches are based on inducing controlled apoptosis in tumor cells.
Although a number of apoptosis-induction approaches are available, site-specific delivery of …

Current treatments for advanced hepatocellular carcinoma (HCC) have limited success in
improving patients' quality of life and prolonging life expectancy. The clinical need for more …

Vesicular stomatitis virus (VSV), a negative-strand RNA virus of the Vesiculovirus genus, has
demonstrated encouraging anti-neoplastic activity across multiple human cancer types. VSV …

Oncolytic virus (OV) therapy takes advantage of common cancer characteristics, such as
defective type I interferon (IFN) signaling, to preferentially infect and kill cancer cells with …

Background: The use of oncolytic viruses for treatment of cancer marks a significant
alteration in the battle between host and virus. Viruses are confronted by cellular innate …

Vesicular stomatitis virus (VSV) has been shown in laboratory studies to be effective against
a variety of tumors, including malignant brain tumors. However, attenuation of VSV may be …